Silo Pharma Awarded Contract To Its Contract Research Organization Partner, AmplifyBio, For IND-enabling Large Animal GLP Study Of SPC-15 For PTSD
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has awarded a contract to its Contract Research Organization partner, AmplifyBio, for an IND-enabling large animal GLP study of SPC-15, a novel intranasal therapeutic for PTSD. This study advances SPC-15 towards its first-in-human trial.
June 26, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma has awarded a contract to AmplifyBio for an IND-enabling GLP study of SPC-15, a novel intranasal therapeutic for PTSD. This is a significant step towards the first-in-human trial of SPC-15.
The contract with AmplifyBio for the GLP study of SPC-15 is a critical step for Silo Pharma as it moves towards the first-in-human trial. This development is likely to positively impact the stock price in the short term due to the advancement in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100